Inhaled nitric oxide for treating pain crises in people with sickle cell disease.
CONCLUSIONS: The currently available trials do not provide sufficient evidence to determine the effects (benefits or harms) of using inhaled nitric oxide to treat pain (vaso-occlusive) crises in people with sickle cell disease. Large-scale, long-term trials are needed to provide more robust data in this area. Patient-important outcomes (e.g. measures of pain and time to pain resolution and amounts of analgesics used), as well as use of healthcare services should be measured and reported in a standardized form.
PMID: 31603241 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Aboursheid T, Albaroudi O, Alahdab F Tags: Cochrane Database Syst Rev Source Type: research
More News: Children | Conferences | Cystic Fibrosis | Databases & Libraries | General Medicine | Genetics | Hematology | Pain | Palliative | Palliative Care | Pediatrics | Sickle Cell Anemia | Study | UK Health